On May 3, 2022 SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, reported that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, in Las Vegas, Nevada and at the H.C. Wainwright Global Investment Conference on May 25, in Miami, Florida (Press release, SQZ Biotech, MAY 3, 2022, View Source [SID1234613438]). Presentation times and webcast information are available below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PRESENTATION DETAILS

Tuesday, May 10
Bank of America Securities 2022 Healthcare Conference
5:00-5:30 p.m. ET / 2:00-2:30 p.m. PT
Webcast

Wednesday, May 25
H.C. Wainwright Global Investment Conference
9:30-10:00 a.m. ET
Webcast

Conference webcast details and the company’s most recent corporate overview presentation will be available on the Investors section of the SQZ website. Replays will be available for 90 days.

On May 3, 2022 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, reported that Camille Bedrosian, M.D., the company’s Chief Medical Officer, and Mardi Dier, the company’s Chief Financial Officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:40 PM ET (Press release, Ultragenyx Pharmaceutical, MAY 3, 2022, View Source [SID1234613463]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the presentation will be accessible from the company’s website at View Source The replay of the webcast will be available for 90 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 3, 2022 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported that HOOKIPA’s management team will participate in and present at the following upcoming investor conferences (Press release, Hookipa Pharma, MAY 3, 2022, View Source [SID1234613365]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BofA Securities 2022 Healthcare Conference, May 10-13, Las Vegas
Fireside Chat: May 10, 8:40am PT
2022 RBC Capital Markets Global Healthcare Conference, May 17-18, New York
Fireside Chat: May 17, 4:05pm ET
H.C. Wainwright Global Investment Conference, May 23-26, Miami Beach
Fireside Chat: May 24, 2:00pm ET
Webcasts will be available within the Investors & Media section of HOOKIPA’s website at View Source Archived replays will be accessible for 30 days following each event.

On May 3, 2022 Curium reported it has successfully enrolled and dosed patients in the ECLIPSE Trial. ECLIPSE is a Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard of care hormone therapy in patients with metastatic castration-resistant prostate cancer (Press release, Curium, MAY 3, 2022, View Source [SID1234613389]). The clinical trial is enrolling patients at sites across the U.S. and will be opening clinical trial sites in Europe in 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to see the ECLIPSE clinical trial progress with patients enrolled and treated with 177Lu-PSMA-I&T," said Renaud Dehareng, Curium’s Group CEO. "We are dedicated to redefining the experience of cancer through our trusted legacy in nuclear medicine. The ECLIPSE clinical trial demonstrates our commitment to patients with metastatic castration-resistant prostate cancer in North America and Europe."

"We would like to thank the investigators and healthcare providers at the clinical trial sites for their dedication to patients with metastatic castration-resistant prostate cancer," said Sakir Mutevelic, MD, Curium’s Chief Medical Officer. "Through our collaboration, we are working together to determine the safety and efficacy of this potential new investigational treatment for patients in need."

For more information about the ECLIPSE Trial, visit Curium’s Clinical Trial website or contact Curium’s Clinical Trial team directly at [email protected] with questions or to locate a clinical trial site near you.